Sen. Tina Smith Sells Off Shares of DexCom, Inc. (NASDAQ:DXCM)

Senator Tina Smith (Democratic-Minnesota) recently sold shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in DexCom stock on April 29th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

DexCom Trading Up 6.6%

Shares of NASDAQ:DXCM traded up $3.81 during trading on Friday, reaching $61.63. 11,132,607 shares of the stock were exchanged, compared to its average volume of 5,256,073. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The firm has a market cap of $23.78 billion, a price-to-earnings ratio of 26.34, a price-to-earnings-growth ratio of 1.00 and a beta of 1.40. The firm’s 50-day moving average price is $63.46 and its 200 day moving average price is $65.89.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.32 EPS. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.56 earnings per share for the current fiscal year.

Institutional Trading of DexCom

Hedge funds have recently made changes to their positions in the stock. Gradient Investments LLC grew its position in shares of DexCom by 13.8% during the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after buying an additional 40,343 shares in the last quarter. Nordea Investment Management AB raised its position in shares of DexCom by 118.6% during the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after acquiring an additional 137,986 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of DexCom by 11.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock valued at $14,269,000 after acquiring an additional 21,352 shares in the last quarter. NEOS Investment Management LLC raised its position in shares of DexCom by 58.7% during the 3rd quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after acquiring an additional 65,066 shares in the last quarter. Finally, Peterson Wealth Services raised its position in shares of DexCom by 423.6% during the 3rd quarter. Peterson Wealth Services now owns 28,937 shares of the medical device company’s stock valued at $1,947,000 after acquiring an additional 23,410 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director directly owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the sale, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 4,412 shares of company stock worth $278,143. Corporate insiders own 0.28% of the company’s stock.

Trending Headlines about DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom outlined a 2030 growth plan calling for at least 10% annual revenue growth through 2030, along with margin targets that suggest improving profitability over time. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: The company authorized a new $1 billion share buyback, which can support the stock by signaling confidence in future cash flow and returning capital to shareholders. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: Management also highlighted next-generation products, including the G8 glucose sensor and dual-analyte sensing, which could expand DexCom’s competitive position and addressable market. Dexcom to add 2 board directors with activist investor Elliott
• Positive Sentiment: DexCom and Elliott Investment Management agreed to add two independent directors to the board and revise governance, a move that may improve oversight and strategic execution. Dexcom to appoint two directors, revamp board committee with Elliott
• Neutral Sentiment: Wall Street sentiment remains constructive overall, with a “Moderate Buy” consensus and an average price target above recent trading levels, though there are still some hold and underweight ratings in the mix. Are Wall Street analysts bullish on DexCom’s stock?
• Negative Sentiment: Director Bridgette Heller sold 1,012 shares, but the transaction was small and was made under a pre-arranged trading plan, so it is less likely to be a major negative signal. Bridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) Stock

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DXCM shares. TD Cowen reduced their price target on DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Mizuho set a $75.00 price target on DexCom in a research report on Friday, May 1st. BTIG Research reissued a “buy” rating and set a $85.00 price target on shares of DexCom in a research report on Monday, March 9th. Wells Fargo & Company reduced their price target on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Finally, Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $83.22.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.